Esperion Therapeutics Inc.
| NASDAQ: ESPR | Healthcare / Biotechnology / USA |
| 27.54 | +0.6500 | +2.42% | Vol 302.37K | 1Y Perf -31.18% |
| Apr 20th, 2021 16:00 DELAYED |
| BID | 26.51 | ASK | 27.69 | ||
| Open | 26.96 | Previous Close | 26.89 | ||
| Pre-Market | - | After-Market | 27.54 | ||
| - - | - -% |
| Target Price | 50.38 | Analyst Rating | Strong Buy 1.29 | |
| Potential % | 82.93 | Finscreener Ranking | ★★★★+ 55.82 | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 53.57 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★+ 56.58 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 775.42M | Earnings Rating | Strong Buy | |
| Price Range Ratio 52W % | 12.20 | Earnings Date | 4th May 2021 |
Today's Price Range 26.6327.66 | 52W Range 23.9053.73 | 5 Year PE Ratio Range -6.40-8.00 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 1.44% | ||
| 1 Month | -6.29% | ||
| 3 Months | 8.21% | ||
| 6 Months | -14.58% | ||
| 1 Year | -31.18% | ||
| 3 Years | -62.63% | ||
| 5 Years | 43.89% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -98.24 | |||
ROE last 12 Months | 385.82 | |||
ROA (5Y Avg) | -49.14 | |||
ROA last 12 Months | -48.93 | |||
ROC (5Y Avg) | -115.11 | |||
ROC last 12 Months | -194.99 | |||
Return on invested Capital Q | -149.95 | |||
Return on invested Capital Y | -176.18 | |||
Assets Turnover | 0.80 | |||
Receivables Turnover | - |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -5.00 | ||||
| 80.52 | ||||
| 3.37 | ||||
| - | ||||
| -26.20 | ||||
| -3.10 | ||||
| -7.91 | ||||
| -3.44 | ||||
| 641.22M | ||||
| Forward PE | -5.36 | |||
| PEG | -0.30 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 3.20 | ||||
| 3.70 | ||||
| 0.31 | ||||
| 0.75 | ||||
| -5.30 | ||||
| Leverage Ratio | -223.70 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 99.00 | ||||
| -38.00 | ||||
| -37.80 | ||||
| - | ||||
| -25.21 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 225.71M | ||||
| 8.02 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -3.76 | -3.89 | -3.46 |
| Q03 2020 | -3.52 | -3.07 | 12.78 |
| Q02 2020 | 2.13 | 4.32 | 102.82 |
| Q01 2020 | -3.14 | -2.84 | 9.55 |
| Q04 2019 | -2.71 | -2.26 | 16.61 |
| Q03 2019 | -2.01 | -2.52 | -25.37 |
| Q02 2019 | -1.86 | -2.01 | -8.06 |
| Q01 2019 | 1.32 | 3.07 | 132.58 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 3/2021 QR | -1.95 | 19.09 | Positive |
| 6/2021 QR | -2.56 | 16.88 | Positive |
| 12/2021 FY | -9.56 | 19.80 | Positive |
| 12/2022 FY | -5.04 | 20.13 | Positive |
| Next Report Date | 4th May 2021 |
| Estimated EPS Next Report | -1.95 |
| Estimates Count | 6 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 302.37K |
| Shares Outstanding | 28.16M |
| Trades Count | 3.84K |
| Dollar Volume | 17.22M |
| Avg. Volume | 752.84K |
| Avg. Weekly Volume | 413.55K |
| Avg. Monthly Volume | 443.40K |
| Avg. Quarterly Volume | 718.34K |
Esperion Therapeutics Inc. (NASDAQ: ESPR) stock closed at 27.54 per share at the end of the most recent trading day (a 2.42% change compared to the prior day closing price) with a volume of 306.78K shares and market capitalization of 775.42M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 479 people. Esperion Therapeutics Inc. CEO is Timothy M. Mayleben.
The one-year performance of Esperion Therapeutics Inc. stock is -31.18%, while year-to-date (YTD) performance is 5.92%. ESPR stock has a five-year performance of 43.89%. Its 52-week range is between 23.9 and 53.73, which gives ESPR stock a 52-week price range ratio of 12.20%
Esperion Therapeutics Inc. currently has a PE ratio of -5.00, a price-to-book (PB) ratio of 80.52, a price-to-sale (PS) ratio of 3.37, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -48.93%, a ROC of -194.99% and a ROE of 385.82%. The company’s profit margin is -25.21%, its EBITDA margin is -37.80%, and its revenue ttm is $225.71 Million , which makes it $8.02 revenue per share.
Of the last four earnings reports from Esperion Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-1.95 for the next earnings report. Esperion Therapeutics Inc.’s next earnings report date is 04th May 2021.
The consensus rating of Wall Street analysts for Esperion Therapeutics Inc. is Strong Buy (1.29), with a target price of $50.38, which is +82.93% compared to the current price. The earnings rating for Esperion Therapeutics Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Esperion Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Esperion Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 11.78, ATR14 : 1.83, CCI20 : -80.12, Chaikin Money Flow : -0.06, MACD : -0.80, Money Flow Index : 43.66, ROC : -4.14, RSI : 52.34, STOCH (14,3) : 41.32, STOCH RSI : 0.72, UO : 50.59, Williams %R : -58.68), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Esperion Therapeutics Inc. in the last 12-months were: Timothy M. Mayleben (Option Excercise at a value of $22 427)
Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. The firm has Business of researching, developing and commercializing therapies for the treatment of patients with the elevated LDL-C operating segment.
CEO: Timothy M. Mayleben
Telephone: +1 734 887-3903
Address: 3891 Ranchero Drive, Ann Arbor 48108, MI, US
Number of employees: 479
